Iranian missile charges an attempt to divert attention from Jerusalem issue
Nikki Haley Says Iran Is Violating UN Rules
A daily cup of hot tea may lower glaucoma risk
Wine glasses now seven times larger than in Georgian times
Creative Planning Purchases 9000 Shares of Editas Medicine, Inc. (NASDAQ:EDIT)
12 August 2017, 10:54 | Rodolfo Wallace
The stock is trading at $19.72 which is well above the 50 day moving average which is $16.99 and marginally over the 200 day moving average of $18.99. Chardan maintained its investment rating on the stock at buy. As of the latest earnings report the EPS was $-3.09 and is estimated to be $-3.04 for the current year with 40,729,000 shares now outstanding. To conclude comes the ratings part in which the company was evaluated with "2" Analysts of WSJ going for Buy ratings in current phase.
Several research analysts have commented on the company. Finally, Driehaus Capital Management LLC increased its stake in shares of Editas Medicine by 169.8% in the first quarter. This is well above the stock's Wednesday closing price of $17.98 each.
On the other hand Editas Medicine Cmn (NASDAQ:EDIT) has Relative Strength Index (RSI 14) of 65.92 along with Average True Range (ATR 14) of 1.17. State Street Corp boosted its stake in shares of Editas Medicine by 2.4% in the fourth quarter. Cann assumed coverage on shares of Editas Medicine in a report on Monday, July 17th. The business's revenue was down 8.8% on a year-over-year basis. (EDIT) on Wednesday reported a loss of $26.4 million in its second quarter. Research firm Zacks lifted Editas Medicine from a "hold" recommendation to a "buy" recommendation and fixed a $19.00 price target for The corporation in a note on Wed, Jul 12th. crowd sourced stock rating company Vetr lifted Editas Medicine from a "buy" recommendation to a "strong-buy" recommendation and fixed a $27.14 target price for The corporation in a note on Mon, Mar 20th.
COPYRIGHT VIOLATION WARNING: "Editas Medicine, Inc". The company had revenue of $3.10 million for the quarter, compared to the consensus estimate of $2.20 million.
Taking a closer look into the volatility on shares of CRISPR Therapeutics AG (:CRSP), we notice that the stock is 13.39% off of the 20-Day Simple Moving Average. And it remains to be seen which target price EDIT can achieve without sacrificing much as the company is holding a -8.28% fall for the past twelve months. The stock now has a Market Cap of $14.76B. Bank of America Corp DE now owns 5,936 shares of the company's stock worth $133,000 after buying an additional 2,489 shares during the period. Of those insider trades, 39,000 shares of Editas Medicine, Inc. were purchased and 1,000,000 shares were sold.
Presently Editas Medicine, Inc. The firm owned 9,101 shares of the company's stock after buying an additional 9,000 shares during the period. Next quarter's EPS is estimated at $-0.78 with next year's EPS anticipated to be $-3.20. Driehaus Capital Management has an ownership of 125,684 stocks of the firms shares valued $2,805,000 after scooping up an extra 79,104 shares through out the quarter. large institution funds own 67.87% of the firms stock. Hershey Trust Co. purchased a new stake in shares of Editas Medicine during the second quarter worth approximately $244,000.
On July 18, 2017 Oppenheimer initiated coverage giving it an initial rating of "Perform". Editas Medicine reported sales of $3.39 million during the same quarter last year, which suggests a negative year-over-year growth rate of 15%. Also, Director Boris Nikolic bought 35,000 shares of the company's stock in a transaction on Friday, June 2nd. A total number of 5 analysts provided estimations over revenues. The shares were bought at an average price of $14.15 per share, for a total transaction of $56,600.00. The Director now owns $47,551,448 of the stock per the Form 4 SEC filing. If you are accessing this report on another publication, it was illegally copied and republished in violation of global trademark & copyright laws. The original version of this news story can be accessed at https://baseballnewssource.com/markets/editas-medicine-inc-nasdaqedit-raised-to-buy-at-zacks-investment-research-updated-updated-updated/1217483.html.
Kevin Bitterman, Director disclosed the sale of 1,000,000 shares of (EDIT). Following the completion of the transaction, the insider now directly owns 4,000 shares in the company, valued at approximately $56,600.
Editas Medicine, Inc is a genome editing company. The information was declared in a document with the Security and Exchange Commission, which is available at this link. The Company is involved in treating patients with genetically defined diseases by correcting their disease-causing genes.
From another technical standpoint, Editas Medicine, Inc. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.
Anna Paquin responds to BBC's viral clip
The True Blood actress became a hot topic on social media after a news video accidentally displayed her breasts to audiences. Actress Anna Paquin expressed delight after her breasts made a surprise appearance on the BBC's ten o'clock news.
Trump warns North Korea against attacking Guam
Referring to an "imminent missile threat", it includes advice like: "Do not look at the flash or fireball - it can blind you". The president called the United States military "incredible, "rock solid" and "the best in the world by a factor of five".
For Honor Free Weekend & 50% Discount Is Now Live on PS4
Stark believes that the release of the PS4 Pro and Xbox One X will lead to Microsoft and Sony lowering the price of core models. The basic tutorial will help you find your footing, and we've got a few more tips to help you hit the ground running.
Danish submarine creator arrested over missing reporter
He has denied responsibility for the fate of 30-year-old Kim Wall, saying she had disembarked before his vessel went down. Madsen (46) financed his submarine project through crowdfunding and completed the submarine, the UC3 Nautilus, in 2008.
Political tensions continue to weigh on world stocks
Avis Budget Group slumped 9.9 percent after the vehicle rental company cut its guidance following a weak second quarter. Investors instead turned to safe-haven assets such as gold , pushing it to a two-month high, and the Japanese yen rose.